drugset / Trial / NCT00542295

Efficacy and Safety of Meteospasmyl® in Irritable Bowel Syndrome

NCT00542295

Phase 4 Completed 400 enrolled Laboratoires Mayoly Spindler
RandomizedParallel-groupDouble-blindTreatment

Summary

To assess the effectiveness of alverine citrate and simeticone on IBS symptoms according to the latest recommended design

Timeline

Start
2007-07
Primary completion
2008-07
Completion
2008-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Alverine Small molecule
Subject simeticone Unknown